ProfoundBio
普方生物
ProfoundBio (普方生物) is a clinical-stage biotech company focused on novel antibody therapies for cancer patients, built around an in-house antibody-drug conjugate (ADC) platform. Its disclosed pipeline targeted both solid tumors and hematologic malignancies — including rinatabart sesutecan (Rina-S) against FRα, plus ADCs against CD70 and PTK7 and a bispecific ADC, PRO1286. The company was co-founded and led by Dr. Baiteng Zhao (赵柏腾) as CEO and chairman.
Its funding arc ran fast: an oversubscribed $55M+ Series A in July 2021 co-led by Lilly Asia Ventures and LYFE Capital, a $70M Series A+ in June 2022 led by Sequoia China, and a $112M Series B in February 2024. Gaorong Ventures had backed it since the Pre-A round in 2021. Then, in April 2024, Danish biotech Genmab agreed to acquire ProfoundBio for $1.8 billion in all cash — a deal Gaorong's Le Belin called "a landmark event for the biopharma industry in recent years." That acquisition is the company's endpoint as an independent entity: it now sits inside Genmab as part of its ADC pipeline push.
AI-generated — may contain errors, please verify.
Coverage
BlueRun Ventures Portfolio Company NeoImmuneTech Completes $38 Million Financing to Advance First-in-Class "Myeloid Cell Engager" Immunotherapy Pipeline | BlueRun Family
From Technical Platform Validation to Clinical Value
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
Qiming Perspective | Qiming Venture Partners' Kan Chen: China's Innovative Drug Exports Hit Record Highs, Where Is Innovative Drug Investment Heading?
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
Countless Lies About M&A in China, and One Truth
All we hear are footsteps on the stairs, but no one ever comes down.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
Genmab Acquires ProfoundBio for $1.8 Billion | Gaorong Ventures News
Accelerate the development and unlock the full potential of ADC therapies.
Rongbao | Hydrogen energy and battery management tech firms secure new funding; innovative drug targets precise efficacy
Grow, toward the future.
ProfoundBio Closes $112 Million Series B to Advance ADC Drug Candidates Into Pivotal Clinical Development
Delivering breakthrough therapies for cancer patients.
New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
BOSS Zhipin Completes Dual Primary Listing, Baijiayun Debuts on Nasdaq, Gaorong Ventures Earns Multiple Accolades | Gaorong Monthly · December
Racing Into 2023
From Big Pharma to Biotech: Four Industry Leaders on How Innovative Drugs Can Balance Speed and Quality | Ronghui
Speed matters, but getting it right matters more.
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
ProfoundBio Closes $70 Million Series A+ Round to Advance Novel Antibody-Drug Conjugate Clinical Development
Accelerate preclinical development across multiple pipelines while further deepening and expanding the ADC innovative technology platform.
Chips, Energy Storage, and LiDAR Accelerate Commercialization; Robotics and SaaS Expand Globally | Rongbao · May
Sailing through the waves, striving upstream.
Rongbao · July | Multiple Companies Close New Funding Rounds, Take the Lead in Their Sectors; Pinduoduo's Olympic Season Boosts Sports Consumption for All
Continue to invest in innovative companies in new consumer brands, new technologies, healthcare, and other sectors.
Platonic Bio Closes Oversubscribed $55 Million Series A to Accelerate ADC Drug and Immuno-Oncology Platform Development
Enabling best-in-class and first-in-class ADCs to advance into clinical development.
